Intrapulmonary administration of polynucleotide toll-like receptor 9 agonists for treating cancer of the lung

Inventors

Guiducci, Cristiana • Coffman, Robert L.

Assignees

Dynavax Technologies Corp

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-9993495-B2

Patent

Publication Date

2018-06-12

Expiration Date


Abstract

The present disclosure relates to methods for treating cancer by intrapulmonary administration of a polynucleotide Toll-like receptor 9 agonist. The methods of the present disclosure are suitable for treating primary cancer of the lung, as well as metastatic cancer to the lung and extra pulmonary cancers thereof. Additionally, the present disclosure provides polynucleotide Toll-like receptor 9 agonists with immune stimulatory and toxicity profiles suitable for intrapulmonary administration.

Core Innovation

The disclosure describes treatment of lung cancer by intrapulmonary administration of a phosphorothioate-linked TLR9 agonist polynucleotide. It also describes pharmaceutical compositions containing an isolated polynucleotide and a pharmaceutically acceptable excipient, as well as combination treatment with an inhibitory immune checkpoint agent. The partial content identifies D60-7 as one polynucleotide and describes inhalation devices for delivery.

The background section is not included in the partial content, so the problem being solved is not explicitly described in patent. The supplied summary reports that shortened variants retain IFN-̴̵̶̷̸̡̢̧̨̛̖̗̘̙̜̝̞̟̠̣̤̥̦̩̪̫̬̭̮̯̰̱̲̳̹̺̻̼͇͈͉͍͎́̀̂̃̄̅̆̇̈̉̊̋̌̍̎̏̐̑̒̓̔̽̾̿̀́͂̓̈́͆͊͋͌̕̚ͅ͏͓͔͕͖͙͚͐͑͒͗͛ͣͤͥͦͧͨͩͪͫͬͭͮͯ͘͜͟͢͝͞͠͡Αα potency while producing lower maximum IFN-α levels, and that mouse studies show less lung inflammation and weight loss than with D60-1. It also reports improved survival and reduced lung metastases in a 4T1 model with anti-PD-1.

Claims Coverage

The partial content identifies two independent claims. The first covers a method of treating lung cancer through intrapulmonary delivery of a specified phosphorothioate-linked polynucleotide. The second covers cancer treatment using a pharmaceutical composition containing an isolated polynucleotide and a pharmaceutically acceptable excipient.

Intrapulmonary treatment of lung cancer

Claim 1 recites treating cancer of the lung in a mammalian subject by intrapulmonary delivery of an effective amount of a polynucleotide with a specified sequence pattern and at least one phosphorothioate linkage. Dependent claims identify alternative polynucleotide sequences, treatment outcomes, cytokine secretion, combination treatment, and a limit on lung toxicity associated with repeated administration.

Cancer treatment using a pharmaceutical composition

Claim 31 recites treating cancer in a mammalian subject by administering a pharmaceutical composition comprising an isolated polynucleotide and a pharmaceutically acceptable excipient. The polynucleotide has a specified sequence pattern and at least one phosphorothioate linkage. Dependent claims specify intrapulmonary administration or injection routes, delivery devices, and alternative polynucleotide sequences.

The two independent claims cover a method of intrapulmonary lung cancer treatment and a method of cancer treatment using a pharmaceutical composition. Both require a specified phosphorothioate-linked polynucleotide; the dependent claims add sequence alternatives, administration routes and devices, combination treatments, and treatment-response limitations.

Stated Advantages

Shortened variants retain IFN-α potency while producing lower maximum IFN-α levels.

In mouse studies, shortened variants produce less lung inflammation and weight loss than D60-1.

In a 4T1 lung-metastasis model, D60-7 combined with anti-PD-1 improves survival and reduces lung metastases beyond either agent alone.

Documented Applications

Treatment of lung cancer by intrapulmonary delivery of a polynucleotide.

Cancer treatment using a pharmaceutical composition containing an isolated polynucleotide and a pharmaceutically acceptable excipient.

Combination treatment with an inhibitory immune checkpoint agent, including anti-PD-1.

Intrapulmonary delivery using a nebulizer, metered-dose inhaler, sprayer, or dry-powder inhalation device.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.